Avalo Therapeutics, Inc.
Description
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
About
CEO
Dr. Garry A. Neil M.D.
Employees
19
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
540 Gaither Road, Rockville, MD 20850, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 5, 2025 | — | — | — | — |
| Aug 11, 2025 | — | — | — | — |
| May 12, 2025 | — | — | — | — |
| Mar 27, 2025 | -1.29 | — | — | — |
| Nov 7, 2024 | -1.19 | -1.25 | -0.06 | 5.04% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 0 | — | 0 |
| Average estimate | — | 0.00 | — | 0.00 |
| Low estimate | — | 0.00 | — | 0.00 |
| High estimate | — | 0.00 | — | 0.00 |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year
—
Next year (Dec 2025)
—
Next 5 years (per annum)
-1.084%
Past 5 years (per annum)
-1.084%
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 1.92M | 18.05M | 5.40M | 6.70M | 6.75M |
| Cost of revenue | 1.28M | 3.43M | 1.49M | 300,000 | -566,523 |
| Gross profit | 640,000 | 14.62M | 3.91M | 6.40M | 7.32M |
| Operating expense | |||||
| Research & development | 13.78M | 31.31M | 59.84M | 32.19M | 11.76M |
| Selling general and admin | 10.30M | 20.71M | 24.66M | 19.76M | 11.61M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -23.44M | -37.44M | -82.13M | -47.29M | -17.39M |
| Non operating interest income | |||||
| Income | — | — | — | 48,873 | 121,326 |
| Expense | 3.42M | 4.17M | 2.39M | — | — |
| Other income expense | -4.67M | -20,000 | -20,000 | -19.93M | 1.28M |
| Pretax income | -31.53M | -41.63M | -84.55M | -67.18M | -15.99M |
| Tax provision | 14,000 | 28,000 | -196,000 | -2.79M | 280,316 |
| Net income | -31.54M | -41.66M | -84.38M | -63.50M | -16.07M |
| Basic EPS | -114.00 | -1,063.20 | -2,390.40 | -2,476.80 | -806.40 |
| Diluted EPS | -114.00 | -1,063.20 | -2,390.40 | -2,476.80 | -806.40 |
| Basic average shares | 277,727 | 39,182 | 35,298 | 1.28M | 2.87M |
| Diluted average shares | 277,727 | 39,182 | 35,298 | 1.28M | 2.87M |
| EBITDA | -23.33M | -37.29M | -80.50M | -25.11M | -14.82M |
| Net income from continuing op. | -31.54M | -41.66M | -84.38M | -63.50M | -16.07M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | -1.50M | -5.86M | -4.02M |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 20.99M | 33.37M | 80.21M | 43.76M | 36.11M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 7.42M | 13.17M | 54.59M | 18.92M | 3.61M |
| Other short term investments | — | — | — | — | 7.63M |
| Accounts receivable | — | — | 1.06M | 2.18M | 1.00M |
| Other receivables | 136,000 | 1.92M | 3.74M | 2.21M | 4.24M |
| Inventory | — | 20,000 | 38,000 | 3,000 | 21,334 |
| Prepaid assets | — | — | 2.37M | 2.66M | 706,968 |
| Restricted cash | 1,000 | 15,000 | 51,000 | 38,000 | 17,535 |
| Assets held for sale | — | — | — | — | 497,577 |
| Hedging assets | — | — | — | — | — |
| Other current assets | 843,000 | 1.29M | 2.37M | 2.66M | 706,968 |
| Non current assets | |||||
| Properties | 1.33M | 1.75M | 2.00M | 918,000 | 718,628 |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 282,000 | 336,000 | 241,000 | 209,000 | 149,876 |
| Construction in progress | — | — | — | — | — |
| Leases | 896,000 | 739,000 | 739,000 | 657,000 | 657,328 |
| Accumulated depreciation | -542,000 | -414,000 | -286,000 | -177,000 | -78,169 |
| Goodwill | 21.00M | 28.82M | 28.86M | 30.40M | 31.24M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | 38,000 | 1.59M | 2.43M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 131,000 | 131,000 | 1.23M | 149,000 | 101,945 |
| Total liabilities | 13.69M | 44.28M | 57.13M | 19.19M | 15.11M |
| Current liabilities | |||||
| Accounts payable | 446,000 | 2.88M | 3.37M | 2.57M | 2.08M |
| Accrued expenses | 3.06M | 9.00M | 11.34M | 7.65M | 3.80M |
| Short term debt | 537,000 | 6.46M | 485,000 | 426,000 | 155,815 |
| Deferred revenue | — | 88,000 | — | — | — |
| Tax payable | — | — | — | — | 551,671 |
| Pensions | 580,000 | 2.70M | 4.31M | 3.12M | 1.59M |
| Other current liabilities | — | 480,000 | 9,000 | 1.45M | 3.98M |
| Non current liabilities | |||||
| Long term debt | — | 13.49M | 32.83M | — | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 155,000 | 141,000 | 113,000 | 90,000 | 85,981 |
| Derivative product liabilities | 5.55M | 4.83M | — | — | — |
| Other non current liabilities | 3.37M | 3.71M | 4.30M | 3.88M | 1.11M |
| Shareholders equity | |||||
| Common stock | 1,000 | — | 9,000 | 75,000 | 44,384 |
| Retained earnings | -335.13M | -303.82M | -262.17M | -177.79M | -114.29M |
| Other shareholders equity | — | — | — | — | — |
| Total shareholders equity | 7.30M | -10.92M | 23.08M | 24.56M | 21.00M |
| Additional paid in capital | 342.44M | 292.91M | 285.24M | 202.28M | 135.24M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -31.54M | -41.66M | -84.38M | -63.50M | -16.07M | -40.05M | 11.87M | -16.47M | -10.49M | -16.06M | -13.05M |
| Depreciation | 158,000 | 166,000 | 1.66M | 1.84M | 3.88M | 4.55M | 425,476 | 26,856 | 23,508 | 28,943 | 20,032 |
| Deferred Taxes | 14,000 | 28,000 | 22,000 | 197,000 | 16,743 | -16,745 | -832,629 | — | — | — | — |
| Stock-Based Compensation | 3.48M | 7.55M | 8.17M | 6.79M | 2.53M | 2.43M | 1.16M | 1.69M | 394,748 | 1.09M | 748,648 |
| Other Non-Cash Items | 1.83M | 1.39M | 794,000 | 23.79M | -901,898 | 19.39M | 158,264 | 162,270 | 293,748 | 989,258 | 146,926 |
| Accounts Receivable | 1.78M | 2.88M | -414,000 | -2.79M | 6.78M | 1.25M | -4.43M | -132,472 | — | — | — |
| Accounts Payable | -2.44M | -487,000 | 796,000 | 99,000 | 1.02M | 82,451 | 96,065 | 332,100 | -268,709 | -708,366 | 818,391 |
| Other Assets & Liabilities | 14,000 | 97,000 | -1.08M | 14,118 | -591,547 | 74,318 | -83,649 | -15,107 | 116,666 | -498 | -175,000 |
| Operating Cash Flow | -26.71M | -30.03M | -74.43M | -33.55M | -3.34M | -12.29M | 8.36M | -14.40M | -9.93M | -14.66M | -11.49M |
| Investing Activities | |||||||||||
| Capital Expenditures | 25,000 | -95,000 | -113,000 | -63,000 | -262,013 | -564,415 | -23,325 | -34,883 | -19,984 | -19,502 | -29,268 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | 11.20M | — | 1.43M | -18.89M | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | — | — | — | — | — |
| Sale of Investments | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | -133,000 | -95,000 | -113,000 | 11.13M | -443,002 | 865,461 | -18.91M | -34,883 | -19,984 | -19,502 | -29,268 |
| Financing Activities | |||||||||||
| Long-Term Debt Issuance | — | — | 32.90M | — | — | — | — | — | — | 9.64M | — |
| Long-Term Debt Payments | -21.24M | — | — | — | -256,140 | — | -2.37M | -3.31M | -1.81M | — | — |
| Other Financing Charges | — | — | — | -94,000 | -915,891 | -294,435 | -279,243 | -114,945 | -2.27M | -365,253 | -698,853 |
| Financing Cash Flow | 24.98M | -14.77M | 104.83M | 44.26M | 11.48M | 3.56M | 1.32M | -4.74M | 17.79M | 23.86M | 5.42M |
| Other Cash Details | |||||||||||
| End Cash Position | 7.55M | 13.32M | 54.86M | 19.11M | 3.73M | 10.75M | 2.61M | 5.13M | 21.16M | 11.74M | 3.42M |
| Income Tax Paid | — | — | — | 474,000 | 1.80M | 354,000 | 540,000 | — | — | — | — |
| Interest Paid | 1.93M | 2.93M | 1.59M | — | 1.05M | 525,000 | 72,526 | 348,888 | 568,299 | 173,514 | — |
| Free Cash Flow | -30.68M | -26.85M | -71.01M | -40.60M | -19.40M | -3.69M | 12.56M | -14.61M | -10.18M | -15.54M | -11.51M |
Error: Invalid format in Holders JSON file.
Article
Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET.
Feb 4, 2025
Article
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization.
Jan 2, 2025
Article
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full exercise of the warrants issued in a March 2024 private placement.
Nov 12, 2024
